University of California, Davis, CA.
Postgraduate Institute of Medical Education & Research, Chandigarh, India.
J Clin Oncol. 2022 Apr 20;40(12):1356-1384. doi: 10.1200/JCO.21.02528. Epub 2021 Dec 22.
To provide evidence-based recommendations to practicing clinicians on management of patients with stage III non-small-cell lung cancer (NSCLC).
An Expert Panel of medical oncology, thoracic surgery, radiation oncology, pulmonary oncology, community oncology, research methodology, and advocacy experts was convened to conduct a literature search, which included systematic reviews, meta-analyses, and randomized controlled trials published from 1990 through 2021. Outcomes of interest included survival, disease-free or recurrence-free survival, and quality of life. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations.
The literature search identified 127 relevant studies to inform the evidence base for this guideline.
Evidence-based recommendations were developed to address evaluation and staging workup of patients with suspected stage III NSCLC, surgical management, neoadjuvant and adjuvant approaches, and management of patients with unresectable stage III NSCLC.Additional information is available at www.asco.org/thoracic-cancer-guidelines.
为临床医生提供治疗 III 期非小细胞肺癌(NSCLC)患者的循证推荐意见。
召集了肿瘤内科、胸外科、放射肿瘤学、肺肿瘤学、社区肿瘤学、研究方法学和宣传专家组成专家小组,进行了文献检索,包括 1990 年至 2021 年发表的系统评价、荟萃分析和随机对照试验。感兴趣的结果包括生存、无疾病或无复发生存和生活质量。专家组利用现有证据和非正式共识制定了循证指南推荐意见。
文献检索确定了 127 项相关研究,为该指南的循证基础提供了信息。
针对疑似 III 期 NSCLC 患者的评估和分期检查、手术管理、新辅助和辅助治疗以及不可切除的 III 期 NSCLC 患者的治疗制定了循证推荐意见。更多信息请访问 www.asco.org/thoracic-cancer-guidelines。